Hugh O'BRien

Hugh O'BRien

Auto-generated profile, based on publicly available information

Hugh O'BRien

Achilles Therapeutics Ltd, London, UK

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2024 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
HOHugh O'BRien
Hugh O'BRien
MSMax Salm
Max Salm
LMLaura T Morton
Laura T Morton
MSMaciej Szukszto
Maciej Szukszto
FOFelix O'FArrell
Felix O'FArrell
SQSergio A Quezada
Sergio A Quezada
Neoantigen immunogenicity prediction is a highly challenging problem in the development of personalised medicines. Low reactivity rates in called neoantigens result in a difficult prediction scenario with limited training datasets. Here we describe ImmugenX, a modular protein language modelling approach to immunogenicity prediction for CD8+ reactive epitopes. ImmugenX comprises of a pMHC encoding module trained on three pMHC prediction tasks, an optional TCR encoding module and a set of context specific immunogenicity prediction head modules. Compared with state-of-the-art models for each task, ImmugenX’s encoding module performs comparably or better on pMHC binding affinity, eluted ligand prediction and stability tasks. ImmugenX outperforms all compared models on pMHC immunogenicity prediction (Area under the receiver operating characteristic curve = 0.619, average precision: 0.514), with a 7% increase in average precision compared to the next best model. ImmugenX shows further improved performance on immunogenicity prediction with the integration of TCR context information. ImmugenX performance is further analysed for interpretability, which locates areas of weakness found across existing immunogenicity models and highlight possible biases in public datasets.

15 December 2023 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
HOHugh O’bRien
Hugh O’bRien
MSMax Salm
Max Salm
LMLaura T. Morton
Laura T. Morton
MSMaciej Szukszto
Maciej Szukszto
FOFelix O’fArrell
Felix O’fArrell
SQSergio A. Quezada
Sergio A. Quezada

15 April 2024 in Nature Cancer
Verified
Journal Article
Open access
PDF file
HOHugh O’bRien
Hugh O’bRien
MSMax Salm
Max Salm
LMLaura T. Morton
Laura T. Morton
MSMaciej Szukszto
Maciej Szukszto
FOFelix O’fArrell
Felix O’fArrell
SQSergio A. Quezada
Sergio A. Quezada

15 October 2022 in Computers in Biology and Medicine
Verified
Journal Article
Open access
HOHugh O’bRien
Hugh O’bRien
JWJohn Whitaker
John Whitaker
MOMark D. O’nEill
Mark D. O’nEill
KGKarine Grigoryan
Karine Grigoryan
HGHarminder Gill
Harminder Gill
SNSteven Niederer
Steven Niederer
Objectives: The aim of this study is to develop an automated method of regional scar detection on clinically standard computed tomography angiography (CTA) using encoder-decoder networks with latent space classification.Background: Localising scar in cardiac patients can assist in diagnosis and guide interventions. Magnetic resonance imaging (MRI) with late gadolinium enhancement (LGE) is the clinical gold standard for scar imaging; however, it is commonly contraindicated. CTA is an alternative imaging modality that has fewer contraindications and is widely used as a first-line imaging modality of cardiac applications.Methods: A dataset of 79 patients with both clinically indicated MRI LGE and subsequent CTA scans was used to train and validate networks to classify septal and lateral scar presence within short axis left ventricle slices. Two designs of encoder-decoder networks were compared, with one encoding anatomical shape in the latent space. Ground truth was established by segmenting scar in MRI LGE and registering this to the CTA images. Short axis slices were taken from the CTA, which served as the input to the networks. An independent external set of 22 cases (27% the size of the cross-validation set) was used to test the best network.Results: A network classifying lateral scar only achieved an area under ROC curve of 0.75, with a sensitivity of 0.79 and specificity of 0.62 on the independent test set. The results of septal scar classification were poor (AUC < 0.6) for all networks. This was likely due to a high class imbalance. The highest AUC network encoded anatomical shape information in the network latent space, indicating it was important for the successful classification of lateral scar. Conclusions: Automatic lateral wall scar detection can be performed from a routine cardiac CTA with reasonable accuracy, without any scar specific imaging. This requires only a single acquisition in the cardiac cycle. In a clinical setting, this could be useful for pre-procedure planning, especially where MRI is contraindicated. Further work with more septal scar present is warranted to improve the usefulness of this approach.

26 May 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
HOHugh O’brien
Hugh O’brien
MSMax Salm
Max Salm
LMLaura T Morton
Laura T Morton
MSMaciej Szukszto
Maciej Szukszto
FOFelix O’farrell
Felix O’farrell
SQSergio A Quezada
Sergio A Quezada
Neoantigen immunogenicity prediction is a highly challenging problem in the development of personalised medicines. Low reactivity rates in called neoantigens result in a difficult prediction scenario with limited training datasets. Here we describe Genesis, a modular protein language modelling approach to immunogenicity prediction for CD8+ reactive epitopes. Genesis comprises of a pMHC encoding module trained on three pMHC prediction tasks, an optional TCR encoding module and a set of context specific immunogenicity prediction head modules. Compared with state-of-the-art models for each task, Genesis’ encoding module performs comparably or better on pMHC binding affinity, eluted ligand prediction and stability tasks. Genesis outperforms all compared models on pMHC immunogenicity prediction (Area under the receiver operating characteristic curve=0.619, average precision: 0.514), with a 7% increase in average precision compared to the next best model. Genesis shows further improved performance on immunogenicity prediction with the integration of TCR context information. Genesis performance is further analysed for interpretability, which locates areas of weakness found across existing immunogenicity models and highlight possible biases in public datasets.